NCT03167411View on ClinicalTrials.gov

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Bexagliflozin

Bexagliflozin tablets, 20 mg

DRUG

Exenatide Injection

Byetta® (Exenatide), 10 ug, bid, subcutaneous injection

Trial Locations (1)

47710

Clinical Research Site, Evansville

Sponsors

Lead Sponsor

Theracos
All Listed Sponsors
lead

Theracos

INDUSTRY

NCT03167411 - Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection | Biotech Hunter | Biotech Hunter